Show simple item record

dc.contributor.advisorMason, Anne
dc.creatorOsgood, Candace R.
dc.date.accessioned2012-11-29T22:15:31Z
dc.date.available2012-11-29T22:15:31Z
dc.date.issued11/29/2012
dc.identifier.urihttp://hdl.handle.net/2376/4225
dc.descriptionThesis (M.Nurs.), College of Nursing, Washington State Universityen_US
dc.description.abstractThis article summarizes the research findings surrounding the identified risk factors that disrupt the methylation process related to the synthesis of L-methylfolate. These risk factors could be included in the practitioners' comprehensive assessment as a tool to enable more accurate identification of patients who might benefit from utilizing L-methylfolate (Deplin®) as a psychiatric intervention. The risk factors that disrupt the methylation process include polymorphisms, certain medications, lifestyle choices, B12 deficiency and other indicators of possible methylation disruption including specific psychiatric disorders and medical diagnoses. With research demonstrating the safety and benefits of L-MTHF as a mono or adjunctive therapy this article proposes that it is a useful tool for practitioners' to increase positive patient outcomes.en_US
dc.languageEnglish
dc.rightsCreative Commons Attribution-NonCommercial-ShareAlike 3.0 United States (CC BY-NC-SA 3.0 US)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us
dc.titleClearing the Air: Identifying Risk Factors of L-Methylfolate Deficiency for L-Methylfolate/Deplin® Intervention
dc.typeElectronic Thesis or Dissertation


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 United States (CC BY-NC-SA 3.0 US)
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-ShareAlike 3.0 United States (CC BY-NC-SA 3.0 US)